261 related articles for article (PubMed ID: 25884645)
1. Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma.
Chow AK; Cheng NS; Lam CS; Ng L; Wong SK; Wan TM; Man JH; Cheung AH; Yau TC; Poon JT; Law WL; Pang RW
Mol Cancer; 2015 Apr; 14():80. PubMed ID: 25884645
[TBL] [Abstract][Full Text] [Related]
2. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
4. RAF265 inhibits the growth of advanced human melanoma tumors.
Su Y; Vilgelm AE; Kelley MC; Hawkins OE; Liu Y; Boyd KL; Kantrow S; Splittgerber RC; Short SP; Sobolik T; Zaja-Milatovic S; Dahlman KB; Amiri KI; Jiang A; Lu P; Shyr Y; Stuart DD; Levy S; Sosman JA; Richmond A
Clin Cancer Res; 2012 Apr; 18(8):2184-98. PubMed ID: 22351689
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
6. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
7. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
8. Gambogic Acid Efficiently Kills Stem-Like Colorectal Cancer Cells by Upregulating ZFP36 Expression.
Wei F; Zhang T; Yang Z; Wei JC; Shen HF; Xiao D; Wang Q; Yang P; Chen HC; Hu H; Chen ZP; Huang Q; Li WL; Cao J
Cell Physiol Biochem; 2018; 46(2):829-846. PubMed ID: 29627822
[TBL] [Abstract][Full Text] [Related]
9. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
Clin Cancer Res; 2011 Oct; 17(20):6482-9. PubMed ID: 21831957
[TBL] [Abstract][Full Text] [Related]
10. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
Pang R; Law WL; Chu AC; Poon JT; Lam CS; Chow AK; Ng L; Cheung LW; Lan XR; Lan HY; Tan VP; Yau TC; Poon RT; Wong BC
Cell Stem Cell; 2010 Jun; 6(6):603-15. PubMed ID: 20569697
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
Chen J; Shen Q; Labow M; Gaither LA
Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556
[TBL] [Abstract][Full Text] [Related]
12. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells.
Zitzmann K; de Toni E; von Rüden J; Brand S; Göke B; Laubender RP; Auernhammer CJ
Endocr Relat Cancer; 2011 Apr; 18(2):277-85. PubMed ID: 21317202
[TBL] [Abstract][Full Text] [Related]
13. The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways.
Barollo S; Bertazza L; Baldini E; Ulisse S; Cavedon E; Boscaro M; Pezzani R; Mian C
Invest New Drugs; 2014 Aug; 32(4):626-35. PubMed ID: 24821574
[TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy.
Feng Y; Gao S; Gao Y; Wang X; Chen Z
Oncotarget; 2016 Dec; 7(49):81402-81409. PubMed ID: 27833077
[TBL] [Abstract][Full Text] [Related]
15. Pien Tze Huang inhibits the proliferation, and induces the apoptosis and differentiation of colorectal cancer stem cells via suppression of the Notch1 pathway.
Qi F; Wei L; Shen A; Chen Y; Lin J; Chu J; Cai Q; Pan J; Peng J
Oncol Rep; 2016 Jan; 35(1):511-7. PubMed ID: 26530025
[TBL] [Abstract][Full Text] [Related]
16. Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.
Toden S; Tran HM; Tovar-Camargo OA; Okugawa Y; Goel A
Oncotarget; 2016 Mar; 7(13):16158-71. PubMed ID: 26930714
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells.
Buhrmann C; Yazdi M; Popper B; Shayan P; Goel A; Aggarwal BB; Shakibaei M
Nutrients; 2018 Jul; 10(7):. PubMed ID: 30002278
[No Abstract] [Full Text] [Related]
18. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
Abdalla AN; Malki WH; Qattan A; Shahid I; Hossain MA; Ahmed M
Molecules; 2021 Jan; 26(2):. PubMed ID: 33440689
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
